在炎症和与压力相关的疾病中的JAK-STAT信号:对治疗干预的含义
Alexey Sarapultsev1,2, Evgenii Gusev3,4, Maria Komelkova3,4
1Russian-Chinese Education and Research Center of System Pathology, South Ural State University, 454080, Chelyabinsk, Russia. a.sarapultsev@gmail.com.
简氏激酶-STAT通路 (JAK-STAT) 对于细胞信号传递至关重要,并与炎症和中枢神经系统疾病有关. 新的研究探索了JAK抑制剂在免疫之外的更广泛应用,包括神经和与压力相关的疾病.
科学领域:
- 蜂信号传输是如何进行的
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
背景情况:
- 简氏酶信号转换器和转录激活器 (JAK-STAT) 途径对于细胞信号传递,调节炎症,压力和免疫反应至关重要.
- JAK-STAT通路的失调与免疫缺陷,恶性瘤和神经炎症疾病有关.
- 目前的JAK抑制剂 (Jakinibs) 主要用于免疫和炎症性疾病.
研究的目的:
- 扩大对JAK-STAT途径的理解,超越传统的免疫学背景.
- 探索JAK-STAT信号在与压力相关的疾病和中枢神经系统 (CNS) 功能中的作用.
- 审查JAK抑制剂的最新进展及其治疗潜力.
主要方法:
- 对JAK-STAT途径现有研究的文献综述.
- 对研究中枢神经系统和与压力有关的疾病中JAK-STAT的研究分析.
- 检查JAK抑制剂治疗的最新发展.
主要成果:
- JAK-STAT通路在中枢神经系统功能中起着重要作用,包括在皮质,海马和小脑中.
- 该途径影响神经传导和血清素受体,影响情绪和压力障碍.
- 最近的发现证明了雅基尼布在诸如类风湿性关节炎等慢性疾病中的有效性,这表明其适用性更广泛.
结论:
- JAK-STAT通路的影响扩展到神经系统和与压力相关的疾病,提供新的治疗点.
- 异形特异性抑制剂 (例如,菲尔戈提尼布,乌帕达西提尼布) 的进步有望提高特异性和减少副作用.
- 与Jakinibs和单克隆抗体的联合疗法可以改善各种疾病的治疗疗效.
更多相关视频
07:12Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
12:50Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
相关概念视频
The JAK-STAT Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
